Johnson & Johnson’s “Class 1 new drug for prostate cancer” approved for clinical trials in China
October 18, 2024
Source: drugdu
67
On October 12, according to the official website of CDE, Johnson & Johnson's Class 1 new drug JNJ-78278343 injection obtained implicit approval for clinical trials and is suitable for the treatment of adult male patients with advanced prostate cancer.
According to public information, JNJ-78278343 is a KLK2-CD3 bispecific antibody and T cell redirection product, which is designed to target KLK2 and induce T cell activation by binding to CD3 on T cells. This product has potential immunomodulatory and anti-tumor activity. After administration, it can bind to CD3 on T cells and KLK2 on tumor cells expressing KLK2, thereby redirecting T cells to tumor cells expressing KLK2, resulting in T cell-mediated lysis of KLK2-expressing tumor cells.
At present, Johnson & Johnson has conducted a number of studies on JNJ-78278343 for prostate cancer internationally. Among them, the Phase 1 study of JNJ-78278343 monotherapy for advanced prostate cancer is expected to be initially completed on November 30, 2024.
The clinical trial application for JNJ-78278343 injection was successfully approved by NMPA, and Johnson & Johnson may conduct further research on it in China .
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
- Regeneron’s midlife crisis November 22, 2024
- This “excellent hospital director” took the initiative to explain the problem November 22, 2024
- The director of the National Medical Insurance Bureau expressed his position to promote direct settlement of medical insurance November 22, 2024
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
